These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32072462)

  • 1. The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
    Marschallinger J; Altendorfer B; Rockenstein E; Holztrattner M; Garnweidner-Raith J; Pillichshammer N; Leister I; Hutter-Paier B; Strempfl K; Unger MS; Chishty M; Felder T; Johnson M; Attems J; Masliah E; Aigner L
    Neurotherapeutics; 2020 Jul; 17(3):1061-1074. PubMed ID: 32072462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
    Wallin J; Svenningsson P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
    Dey M; Singh RK
    Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.
    Michael J; Zirknitzer J; Unger MS; Poupardin R; Rieß T; Paiement N; Zerbe H; Hutter-Paier B; Reitsamer H; Aigner L
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.
    Han B; Zhang YY; Ye ZQ; Xiao Y; Rasouli J; Wu WC; Ye SM; Guo XY; Zhu L; Rostami A; Wang LB; Zhang Y; Li X
    Immunology; 2021 Jun; 163(2):185-200. PubMed ID: 33480040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteinyl leukotriene receptor-1 as a potential target for host-directed therapy during chronic schistosomiasis in murine model.
    Mosala P; Mpotje T; Abdel Aziz N; Ndlovu H; Musaigwa F; Nono JK; Brombacher F
    Front Immunol; 2024; 15():1279043. PubMed ID: 38840916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
    Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
    Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
    Sutton SS; Magagnoli J; Cummings TH; Hardin JW
    Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the cysteinyl leukotriene pathways increases survival of RGCs and reduces microglial activation in ocular hypertension.
    Trost A; Motloch K; Koller A; Bruckner D; Runge C; Schroedl F; Bogner B; Kaser-Eichberger A; Strohmaier C; Ladek AM; Preishuber-Pfluegl J; Brunner SM; Aigner L; Reitsamer HA
    Exp Eye Res; 2021 Dec; 213():108806. PubMed ID: 34715090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Montelukast Ameliorates Scopolamine-induced Alzheimer's Disease: Role on Cholinergic Neurotransmission, Antioxidant Defence System, Neuroinflammation and Expression of BDNF.
    Yerraguravagari B; Penchikala NP; Kolusu AS; Ganesh GS; Konduri P; Nemmani KVS; Samudrala PK
    CNS Neurol Disord Drug Targets; 2024; 23(8):1040-1055. PubMed ID: 37779395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
    Mohamed MZ; Zenhom NM
    Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Montelukast in pediatric asthma management.
    Walia M; Lodha R; Kabra SK
    Indian J Pediatr; 2006 Apr; 73(4):275-82. PubMed ID: 16816486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
    Al-Kuraishy HM; Al-Gareeb AI; Almulaiky YQ; Cruz-Martins N; El-Saber Batiha G
    Eur J Pharmacol; 2021 Aug; 904():174196. PubMed ID: 34004207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
    Hoxha M; Rovati GE; Cavanillas AB
    Eur J Clin Pharmacol; 2017 Jul; 73(7):799-809. PubMed ID: 28374082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
    Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
    Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
    Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
    Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma.
    Kotani H; Kishi R; Mouri A; Sashio T; Shindo J; Shiraki A; Hiramatsu T; Iwata S; Taniguchi H; Nishiyama O; Iwata M; Suzuki R; Gonda H; Niwa T; Kondo M; Hasegawa Y; Kume H; Noda Y
    J Clin Pharm Ther; 2012 Feb; 37(1):112-6. PubMed ID: 21385196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
    Shimbori C; Shiota N; Okunishi H
    Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Montelukast: more than a cysteinyl leukotriene receptor antagonist?
    Tintinger GR; Feldman C; Theron AJ; Anderson R
    ScientificWorldJournal; 2010 Dec; 10():2403-13. PubMed ID: 21170491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.
    Gupta S; Singh P; Sharma B
    Curr Hypertens Rev; 2024; 20(1):23-35. PubMed ID: 38192137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.